口服辅酶Q10补充治疗可更好地保护原发性辅酶Q10缺乏所致激素抵抗型肾病综合征患者的肾功能
该研究分析了116例因COQ2、COQ6或COQ8B基因双等位致病变异导致原发性辅酶Q10缺乏并接受辅酶Q10补充治疗的患者,中位随访2年。在41例治疗开始时为慢性肾脏病1-4期的18岁以下患者中,与按基因型、年龄、肾功能和蛋白尿匹配的未治疗队列相比,辅酶Q10补充与12个月时蛋白尿持续显著降低88%相关,5年无肾衰竭生存率显著更高(62% vs 19%)。作者认为所有确诊原发性辅酶Q10缺乏的患者均应早期并终身接受辅酶Q10补充治疗。
要点
- 辅酶Q10补充与12个月时蛋白尿持续显著降低88%相关。
- 治疗组5年无肾衰竭生存率62% vs 未治疗组19%。
- COQ6疾病中蛋白尿完全缓解更常见,治疗副作用不常见且轻微。
核心结论
- 所有确诊原发性辅酶Q10缺乏的患者均应早期并终身接受辅酶Q10补充治疗,以减缓肾脏疾病进展并预防其他器官进一步损伤。
研究设计与样本
- 全球性收集并分析116例因COQ2、COQ6或COQ8B基因双等位致病变异导致原发性辅酶Q10缺乏并接受辅酶Q10补充治疗的患者资料,中位治疗随访时间为2年。
- 在41例治疗开始时为慢性肾脏病1-4期的18岁以下患者中分析肾脏生存,并与按基因型、年龄、肾功能和蛋白尿匹配的未治疗队列比较。
主要发现
- 辅酶Q10补充与12个月时蛋白尿持续显著降低88%相关。
- COQ6疾病中蛋白尿完全缓解更常见。
- 辅酶Q10补充组5年无肾衰竭生存率62% vs 未治疗组19%,差异显著。
- 辅酶Q10补充组一般状况和神经系统表现有改善。
- 治疗副作用不常见且轻微。
临床怎么用
- 作者认为所有确诊原发性辅酶Q10缺乏的患者均应早期并终身接受辅酶Q10补充治疗,以减缓肾脏疾病进展并预防其他器官进一步损伤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary Coenzyme Q10 (CoQ10) deficiency is an ultra-rare disorder caused by defects in genes involved in CoQ10 biosynthesis leading to multidrug-resistant nephrotic syndrome as the hallmark kidney manifestation. Promising early results have been reported anecdotally with oral CoQ10 supplementation. However, the long-term efficacy and optimal prescription remain to be established. In a global effort, we collected and analyzed information from 116 patients who received CoQ10 supplements for primary CoQ10 deficiency due to biallelic pathogenic variants in either the COQ2, COQ6 or COQ8B genes. Median duration of follow up on treatment was two years. The effect of treatment on proteinuria was assessed, and kidney survival was analyzed in 41 patients younger than 18 years with chronic kidney disease stage 1-4 at the start of treatment compared with that of an untreated cohort matched by genotype, age, kidney function, and proteinuria. CoQ10 supplementation was associated with a substantial and significant sustained reduction of proteinuria by 88% at 12 months. Complete remission of proteinuria was more frequently observed in COQ6 disease. CoQ10 supplementation led to significantly better preservation of kidney function (5-year kidney failure-free survival 62% vs. 19%) with an improvement in general condition and neurological manifestations. Side effects of treatment were uncommon and mild. Thus, our findings indicate that all patients diagnosed with primary CoQ10 deficiency should receive early and life-long CoQ10 supplementation to decelerate the progression of kidney disease and prevent further damage to other organs.
引用
- Drovandi S, Lipska-Ziętkiewicz BS, Ozaltin F, et al. Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int. 2022. PMID: 35643375. doi:10.1016/j.kint.2022.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。